Hong Kong stock market dynamics: Yi Ming Angke-B (01541.HK) rose more than 7% in the morning, and IMM2510 is expected to fill the clinical gap in the treatment of rear-line lung squamous cell carcinoma.

According to the Securities Times app, Ji Ming Ang Ke-B (01541.HK) rose more than 7% in the morning session, up 2.63% at the time of writing, reporting 3.9 Hong Kong dollars, with a turnover of 1.7963 million Hong Kong dollars.